Verastem (VSTM) Shares Outstanding (Diluted Average) (2016 - 2025)
Verastem's quarterly Shares Outstanding (Diluted Average) came in at $69.3 million in Q4 2025, up 94.07% year-on-year from $35.7 million in Q4 2024, and up 7.35% quarter-over-quarter from $64.6 million in Q3 2025.
Verastem has reported Shares Outstanding (Diluted Average) for 10 years, with the latest figure at $69.3 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 94.07% year-over-year to $69.3 million; the trailing twelve-month figure through Dec 2025 stood at $69.3 million (up 94.07% YoY), and the FY2025 full-year result was $69.3 million, up 94.07% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $69.3 million, up from $64.6 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $200.7 million in Q1 2023, with the low at $14.5 million in Q4 2021.
- Average Shares Outstanding (Diluted Average) over 5 years is $96.6 million, with a median of $64.6 million recorded in 2025.
- Year-over-year, Shares Outstanding (Diluted Average) surged 9379.55% in 2021 and plunged 89.24% in 2023.
- Tracing VSTM's Shares Outstanding (Diluted Average) over 5 years: stood at $14.5 million in 2021, then climbed by 11.03% to $16.1 million in 2022, then soared by 36.66% to $22.1 million in 2023, then soared by 61.93% to $35.7 million in 2024, then jumped by 94.07% to $69.3 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $69.3 million (Q4 2025), $64.6 million (Q3 2025), and $54.2 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 69.31 Mn |
| Sep 30, 2025 | 64.56 Mn |
| Mar 31, 2025 | 54.17 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Sep 30, 2024 | 31.35 Mn |
| Mar 31, 2024 | 26.83 Mn |
| Dec 31, 2023 | 22.05 Mn |
| Sep 30, 2023 | 20.45 Mn |
| Mar 31, 2023 | 200.68 Mn |
| Dec 31, 2022 | 16.14 Mn |
| Sep 30, 2022 | 190.00 Mn |
| Jun 30, 2022 | 186.36 Mn |
| Mar 31, 2022 | 186.26 Mn |
| Dec 31, 2021 | 14.54 Mn |
| Sep 30, 2021 | 179.86 Mn |
| Jun 30, 2021 | 171.99 Mn |
| Mar 31, 2021 | 171.59 Mn |
| Dec 31, 2020 | 153,330.00 |
| Sep 30, 2020 | 147.77 Mn |
| Dec 31, 2019 | 74.58 Mn |
| Sep 30, 2019 | 73.99 Mn |
| Jun 30, 2019 | 73.88 Mn |
| Mar 31, 2019 | 73.85 Mn |
| Dec 31, 2018 | 69.32 Mn |
| Sep 30, 2018 | 73.64 Mn |
| Jun 30, 2018 | 61.26 Mn |
| Mar 31, 2018 | 50.84 Mn |
| Dec 31, 2017 | 38.42 Mn |
| Dec 31, 2016 | 36.99 Mn |